Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033511 · ClinicalTrials.gov registry record · Phase 3
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
A Phase 3 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 3
- Development phase
- 748
- Enrollment target
NCT03033511 is a Phase 3 study that was terminated before completion, run by AbbVie. The registered enrollment target is 748 participants.
The verdict
NCT03033511, a Phase 3 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 748 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Interventions
- DRUG Dexamethasone
- DRUG Rovalpituzumab tesirine
- DRUG Placebo for dexamethasone
- DRUG Placebo for rovalpituzumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033511
The ClinicalTrials.gov registry entry for NCT03033511 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 748 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT03033511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03033511 about?
NCT03033511 is a clinical study titled "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)". This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
What is the current status of trial NCT03033511?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 748 participants. The study started on 2017-02-07. Estimated completion is 2019-11-20.
What interventions are being tested in trial NCT03033511?
The interventions under investigation include: Dexamethasone (DRUG), Rovalpituzumab tesirine (DRUG), Placebo for dexamethasone (DRUG), Placebo for rovalpituzumab tesirine (DRUG).
Who is sponsoring clinical trial NCT03033511?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.